Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 26;20(9):2061.
doi: 10.3390/ijms20092061.

Flavonoids and Insulin-Resistance: From Molecular Evidences to Clinical Trials

Affiliations
Review

Flavonoids and Insulin-Resistance: From Molecular Evidences to Clinical Trials

Benedetta Russo et al. Int J Mol Sci. .

Abstract

Insulin-resistance is one of the main factors responsible for the onset and progression of Metabolic Syndrome (MetS). Among all polyphenols, the effects of flavonoids and their main food sources on insulin sensitivity have been widely evaluated in molecular and clinical studies. The aim of this review is to analyse the data observed in vitro, in vivo and in clinical trials concerning the effects of flavonoids on insulin resistance and to determine the molecular mechanisms with which flavonoids interact with insulin signaling.

Keywords: flavonoids; insulin-resistance; metabolic syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Normal insulin signaling. Insulin binds to the insulin receptor (IR) inducing a conformational change and a rapid autophosphorylation of IR leading to the recruitment and phosphorylation of receptor substrates such as insulin receptor substrate (IRS) and Shc proteins. Shc proteins activate the Ras/mitogen-activated protein kinase (MAPK), whereas IRS proteins mostly activates the phosphoinositide 3-kinase (PI3K)/Akt pathway by recruiting and activating PI3K. In the skeletal muscle and adipose tissue, the PI3K/Akt pathway induces AMP-activated protein kinase (AMPK) phosphorylation and the expression of the glucose transporter type 4 (GLUT4) and its translocation from intracellular vesicles to the cell membrane promoting the uptake of glucose. In the liver, the PI3K/Akt pathway inhibits the expression of phosphoenol pyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6P) suppresses gluconeogenesis and activates glucokinase (GK) and glycogen synthase kinase (GSK), promoting glycogen synthesis. Arrow stimulates, T bar inhibits
Figure 2
Figure 2
Impaired Insulin signaling. Insulin resistance impairs the activation of PI3K/Akt of the skeletal muscle and adipose tissue leading to a decreased GLUT4 expression and translocation, resulting in impaired glucose uptake. Deficits in hepatic insulin signaling release FOXO1 back to the nucleus to promote the expression of PEPCK and G6P genes promoting gluconeogenesis and decrease GK and GSK activation suppressing glycogen synthesis. Arrow with red X: impaired stimulation, T bar with red X: impaired inhibition
Figure 3
Figure 3
Effects of flavonoids on impaired insulin signaling. Flavonoids induce IR and IRS phosphorylation and activate PI3K/Akt pathway and AMPK, promoting GLUT4 translocation in skeletal muscle and adipose tissues. In the liver, the PI3K/Akt pathway activated by flavonoids decreases PEPCK and G6P expression, suppressing gluconeogenesis and increasing GK and GSK expression, promoting glycogen synthesis.

References

    1. Cornier M.A., Dabelea D., Hernandez T.L., Lindstrom R.C., Steig A.J., Stob N.R., van Pelt R.E., Wang H., Eckel R.H. The Metabolic Syndrome. Endocr. Rev. 2008;29:777–822. - PMC - PubMed
    1. Hanley A.J., Karter A.J., Williams K., Festa A., D’Agostino R.B., Wagenknecht L.E., Haffner S.M. Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: The Insulin Resistance Atherosclerosis Study. Circulation. 2005;112:3713–3721. doi: 10.1161/CIRCULATIONAHA.105.559633. - DOI - PubMed
    1. Gami A.S., Witt B.J., Howard D.E., Erwin P.J., Gami L.A., Somers V.K., Montori V.M. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J. Am. Coll. Cardiol. 2007;49:403–414. doi: 10.1016/j.jacc.2006.09.032. - DOI - PubMed
    1. Taylor J.Y., Kraja A.T., de Las Fuentes L., Stanfill A.G., Clark A., Cashion A. An overview of the genomics of metabolic syndrome. J. Nurs. Scholarsh. 2013;45:52–59. doi: 10.1111/j.1547-5069.2012.01484.x. - DOI - PMC - PubMed
    1. Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: Definitions and controversies. BMC Med. 2011;9:48. doi: 10.1186/1741-7015-9-48. - DOI - PMC - PubMed

LinkOut - more resources